RxSight, Inc.

As of November 10, 2021, RxSight, Inc. is considered a risky investment due to its overvaluation and poor financial metrics, including a Price to Book Value of 2.19 and a year-to-date stock return of -72.4%, significantly underperforming the S&P 500.

As of November 10, 2021, RxSight, Inc. is considered overvalued and risky due to negative earnings, poor return ratios, and high valuation metrics compared to its peers, indicating a significant decline in its financial outlook.

As of May 12, 2025, the trend is mildly bearish, supported by daily moving averages and Bollinger Bands, though mixed signals from the MACD indicate some underlying bullishness.

RxSight, Inc. is a small-cap company in the Electronics & Appliances industry, reporting net sales of $38 million and a net loss of $8 million as of March 2025, with a market cap of $548.60 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -9.50%.

As of Jun 18, RxSight, Inc. has a market capitalization of 548.60 million, with net sales of 148.31 million and a net profit of -26.55 million for the latest four quarters. As of Dec 24, shareholder's funds are 281.24 million, and total assets are 321.42 million.